Sökning: onr:"swepub:oai:DiVA.org:uu-14703" >
Growth-differentiat...
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction
-
Kempf, Tibor (författare)
-
- Björklund, Erik (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
- Olofsson, Sylvia, 1955- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
visa fler...
-
- Lindahl, Bertil, 1957- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
Allhoff, Tim (författare)
-
Peter, Timo (författare)
-
Tongers, Jörn (författare)
-
Wollert, Kai C (författare)
-
- Wallentin, Lars, 1943- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
-
visa färre...
-
(creator_code:org_t)
- 2007-10-17
- 2007
- Engelska.
-
Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 28:23, s. 2858-2865
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims Growth-differentiation factor-15 (GDF-15) is a transforming growth factor-beta-related cytokine that is induced in the heart following ischaemia-reperfusion injury. We explored the prognostic utility of GDF-15 in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy. Methods and results Circulating levels of GDF-15 were determined by an immunoradiometric assay in 741 STEMI patients who were included in the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-2 and ASSENT-plus trials. About 72.7% of the patients presented with GDF-15 levels >= 1200 ng/L, the upper limit of normal in apparently healthy elderly individuals. Increased levels of GDF-15 were associated with a higher risk of death during 1-year follow-up. Mortality rates at 1 year were 2.1, 5.0, and 14.0% in patients with GDF-15 levels < 1200, 1200-1800, and > 1800 ng/L, respectively (P < 0.001). GDF-15 remained an independent predictor of mortality after adjustment for clinical variables, troponin T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). GDF-15 provided prognostic information in clinically relevant patient subgroups, defined according to age, gender, cardiovascular risk factors, haemodynamic status, and the TIMI risk score. Moreover, GDF-15 added prognostic information to the established biomarkers of adverse prognosis in STEMI, troponin T, and NT-proBNP. Conclusion GDF-15 is a new biomarker in STEMI that provides prognostic information beyond established clinical and biochemical markers.
Nyckelord
- biomarker
- growth differentiation factor 15
- STEMI
- prognosis
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kempf, Tibor
-
Björklund, Erik
-
Olofsson, Sylvia ...
-
Lindahl, Bertil, ...
-
Allhoff, Tim
-
Peter, Timo
-
visa fler...
-
Tongers, Jörn
-
Wollert, Kai C
-
Wallentin, Lars, ...
-
visa färre...
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Uppsala universitet